AAAAAA
Results:
1-12
|
Results: 12
Authors:
Gerber, JG
Rosenkranz, S
Segal, Y
Aberg, J
D'Amico, R
Mildvan, D
Gulick, R
Hughes, V
Flexner, C
Aweeka, F
Hsu, A
Gal, J
Citation: Jg. Gerber et al., Effect of ritonavir/saquinavir on stereoselective pharmacokinetics of methadone: Results of AIDS clinical trials group (ACTG) 401, J ACQ IMM D, 27(2), 2001, pp. 153-160
Authors:
Becker, S
Fisher, A
Flexner, C
Gerber, JG
Haubrich, R
Kashuba, ADM
Luber, AD
Piscitelli, SC
Citation: S. Becker et al., Pharmacokinetic parameters of protease inhibitors and the Cmin/IC50 ratio:Call for consensus, J ACQ IMM D, 27(2), 2001, pp. 210-211
Authors:
Ratner, L
Lee, J
Tang, SH
Redden, D
Hamzeh, F
Herndier, B
Scadden, D
Kaplan, L
Ambinder, R
Levine, A
Harrington, W
Grochow, L
Flexner, C
Tan, B
Straus, D
Citation: L. Ratner et al., Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy, J CL ONCOL, 19(8), 2001, pp. 2171-2178
Authors:
Raines, CP
Flexner, C
Sun, E
Heath-Chiozzi, M
Lewis, RH
Fields, C
Deetz, C
Apuzzo, L
Eshleman, SH
Jackson, JB
Gallant, JE
Citation: Cp. Raines et al., Safety, tolerability, and antiretroviral effects of ritonavir-nelfinavir combination therapy administered for 48 weeks, J ACQ IMM D, 25(4), 2000, pp. 322-328
Authors:
Flexner, C
Citation: C. Flexner, Dual protease inhibitor therapy in HIV-infected patients: Pharmacologic rationale and clinical benefits, ANN R PHARM, 40, 2000, pp. 649-674
Authors:
Flexner, C
Citation: C. Flexner, HIV genotype and phenotype - Arresting resistance?, J AM MED A, 283(18), 2000, pp. 2442-2444
Authors:
Hendrix, CW
Flexner, C
MacFarland, RT
Giandomenico, C
Fuchs, EJ
Redpath, E
Bridger, G
Henson, GW
Citation: Cw. Hendrix et al., Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers, ANTIM AG CH, 44(6), 2000, pp. 1667-1673
Authors:
Speck, RR
Flexner, C
Tian, CJ
Fu, XF
Citation: Rr. Speck et al., Comparison of human immunodeficiency virus type 1 Pr55(Gag) and Pr160(Gag-Pol) processing intermediates that accumulate in primary and transformed cells treated with peptidic and nonpeptidic protease inhibitors, ANTIM AG CH, 44(5), 2000, pp. 1397-1403
Authors:
Dowell, P
Flexner, C
Kwiterovich, PO
Lanes, MD
Citation: P. Dowell et al., Suppression of preadipocyte differentiation and promotion of adipocyte death by HIV protease inhibitors, J BIOL CHEM, 275(52), 2000, pp. 41325-41332
Authors:
Flexner, C
Abramson, SB
Snyderman, R
Dieterich, DT
Korn, D
Temple, R
Sherwood, L
Goldblatt, D
Citation: C. Flexner et al., Patients, physicians, and clinical trials: The other side of the coins, J INVES MED, 47(8), 1999, pp. 343-357
Authors:
Finzi, D
Blankson, J
Siliciano, JD
Margolick, JB
Chadwick, K
Pierson, T
Smith, K
Lisziewicz, J
Lori, F
Flexner, C
Quinn, TC
Chaisson, RE
Rosenberg, E
Walker, B
Gange, S
Gallant, J
Siliciano, RF
Citation: D. Finzi et al., Latent infection of CD4(+) T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy, NAT MED, 5(5), 1999, pp. 512-517
Authors:
Barditch-Crovo, P
Trapnell, CB
Ette, E
Zacur, HA
Coresh, J
Rocco, LE
Hendrix, CW
Flexner, C
Citation: P. Barditch-crovo et al., The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive, CLIN PHARM, 65(4), 1999, pp. 428-438
Risultati:
1-12
|